1196 infection control & hospital epidemiology october 2015, vol. 36, no. 10
risk factors for hospital mortality and IIAT. Larger cohorts might show more-similar risk factors for these outcomes. Fourth, our definition ofCOP included patients who previously would have been classified as HCAP. However, given the con- troversies surrounding the HCAP definition we chose to simply define patients acquiring Pa-NP outside of the hospital as community-onset. In addition, we did not assess the type of prior antibiotics administered nor did we assess how clinicians made decisions regarding the selection of empirical antibiotic therapy in this cohort. This may have been important, especially if the administration of prior antibiotics gave rise to broader subsequent empirical therapy resulting in less IIAT as suggested by the VAPanalysis. Finally, we did not require the study sites to provide information on the overall number of patients screened or the number of patients with possible Pseudomonas pneu- monia that were excluded for not meeting the entry criteria.We recognize that this is a potential bias of our study, potentially selecting out a cohort of patients with Pseudomonas pneumonia that may not be representative of all patients with this infection. In summary, our study found that for Pa-NP, pneumonia
classification identified patientswith different risks for hospital mortality. Risk factors for hospital mortality also differed by pneumonia classification and multidrug resistance appeared to be a common risk factor for IIAT. These findings suggest that pneumonia classification for P. aeruginosa identifies patients with different mortality risks and specific risk factors for outcome and IIAT.
acknowledgments
Financial support. Cubist Pharmaceuticals. Potential conflicts of interest. S.T.M. reports that he has received
research funding from Cubist, Astellas, Forest, Theravance, Tetraphase, and Pfizer. M.H.K. reports that he has served as a consultant to and/or received research funding from Cubist, Astellas, Pfizer, Forest, Cardeas, the Academy of Infection Management, and Theravance. J.C. reports that he has received consulting or lecture fees from Bayer, Pfizer, Basilea, Astellas, Cubist-Trius, and Kenta-Aridis. H.O. reports that he has served as a consultant and/or speaker and/or received research grants from Astellas, AstraZeneca, Cubist, Gilead, MSD, and Pfizer. All other authors report no conflicts of interest relevant to this article.
Address correspondence to Scott T. Micek, PharmD, St. Louis College of
Pharmacy, 4588 Parkview Pl, St. Louis, Missouri 63110-1088 (scott.
micek@stlcop.edu).
references
1. American Thoracic Society; Infectious Diseases Society of America. Guidelines for the management of adults with hospital- acquired, ventilator-associated, and healthcare-associated pneumonia. Am J Respir Crit Care Med 2005;171:388–416.
2. Kollef MH, Shorr A, Tabak YP, Gupta V, Liu LZ, Johannes RS. Epidemiology and outcomes of health-care-associated pneumo- nia: results from a large US database of culture-positive pneumonia. Chest 2005;128:3854–3862.
3. Sopena N, Sabria M. Multicenter study of hospital-acquired pneumonia in non-ICU patients. Chest 2005;127:213–219.
4. Weber DJ, Rutala WA, Sickbert-Bennett EE, Samsa GP, Brown V, Niederman MS. Microbiology of ventilator-associated pneumo- nia compared with that of hospital-acquired pneumonia. Infect Control Hosp Epidemiol 2007;28:825–831.
5. Esperatti M1, Ferrer M, Theessen A, et al. Nosocomial pneumonia in the intensive care unit acquired by mechanically ventilated versus nonventilated patients. Am J Respir Crit Care Med 2010;182:1533–1539.
6. Wang CY, Jerng JS, Chen KY, et al. Pandrug-resistant Pseudomonas aeruginosa among hospitalised patients: clinical features, risk-factors and outcomes. Clin Microbiol Infect 2006;12:63–68.
7. Tumbarello M, De Pascale G, Trecarichi EM, et al. Clinical outcomes of Pseudomonas aeruginosa pneumonia in intensive care unit patients. Intensive Care Med 2013;39:682–692.
8. Chung DR, Song JH, Kim SH, et al. High prevalence of multidrug-resistant nonfermenters in hospital-acquired pneu- monia in Asia. Am J Respir Crit Care Med 2011;184:1409–1417.
9. Parker CM, Kutsogiannis J, Muscedere J, et al. Ventilator- associated pneumonia caused by multidrug-resistant organisms or Pseudomonas aeruginosa: prevalence, incidence, risk factors, and outcomes. J Crit Care 2008;23:18–26.
10. Zilberberg MD, Shorr AF. Prevalence of multidrug-resistant Pseudomonas aeruginosa and carbapenem-resistant Enter- obacteriaceae among specimens from hospitalized patients with pneumonia and bloodstream infections in the United States from 2000 to 2009. J Hosp Med 2013;8:559–563.
11. Driscoll JA, Brody SL, Kollef MH. The epidemiology, pathogen- esis and treatment of Pseudomonas aeruginosa infections. Drugs 2007;67:351–368.
12. Crouch Brewer S, Wunderink RG, Jones CB, Leeper KV Jr. Ventilator-associated pneumonia due to Pseudomonas aeruginosa. Chest 1996;109:1019–1029.
13. Kollef MH, Chastre J, Clavel M, et al. A randomized trial of 7-day doripenem versus 10-day imipenem-cilastatin for ventilator- associated pneumonia. Crit Care 2012;16:R218.
14. Garnacho-Montero J, Sa-Borges M, Sole-Violan J, et al. Optimal management therapy for Pseudomonas aeruginosa ventilator- associated pneumonia: an observational, multicenter study comparing monotherapy with combination antibiotic therapy. Crit Care Med 2007;35:1888–1895.
15. Micek ST, Reichley RM, KollefMH. Health care-associated pneu- monia (HCAP): empiric antibiotics targeting methicillin-resistant Staphylococcus aureus(MRSA) and Pseudomonas aeruginosa predict optimal outcome. Medicine (Baltimore) 2011;90:390–395.
16. Magiorakos AP, Srinivasan A, Carey RB, et al. Multidrug- resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance. Clin Microbiol Infect 2012;18:268–281.
17. Kollef MH. Broad-spectrum antimicrobials and the treatment of serious bacterial infections: getting it right up front. Clin Infect Dis 2008;47:S3–13.
18. Clinical and Laboratory Standards Institute. Performance standards for antimicrobial susceptibility testing: 19th informational supplement. Wayne, PA: CLSI, 2009:M100–S19.
19. European Committee on Antimicrobial Susceptibility Testing. Breakpoint tables for interpretation of MICs and zone diameters, versions 1.3 and 2.0.
http://www.eucast.org/clinical_breakpoints/. Accessed August 25, 2014.
Page 1 |
Page 2 |
Page 3 |
Page 4 |
Page 5 |
Page 6 |
Page 7 |
Page 8 |
Page 9 |
Page 10 |
Page 11 |
Page 12 |
Page 13 |
Page 14 |
Page 15 |
Page 16 |
Page 17 |
Page 18 |
Page 19 |
Page 20 |
Page 21 |
Page 22 |
Page 23 |
Page 24 |
Page 25 |
Page 26 |
Page 27 |
Page 28 |
Page 29 |
Page 30 |
Page 31 |
Page 32 |
Page 33 |
Page 34 |
Page 35 |
Page 36 |
Page 37 |
Page 38 |
Page 39 |
Page 40 |
Page 41 |
Page 42 |
Page 43 |
Page 44 |
Page 45 |
Page 46 |
Page 47 |
Page 48 |
Page 49 |
Page 50 |
Page 51 |
Page 52 |
Page 53 |
Page 54 |
Page 55 |
Page 56 |
Page 57 |
Page 58 |
Page 59 |
Page 60 |
Page 61 |
Page 62 |
Page 63 |
Page 64 |
Page 65 |
Page 66 |
Page 67 |
Page 68 |
Page 69 |
Page 70 |
Page 71 |
Page 72 |
Page 73 |
Page 74 |
Page 75 |
Page 76 |
Page 77 |
Page 78 |
Page 79 |
Page 80 |
Page 81 |
Page 82 |
Page 83 |
Page 84 |
Page 85 |
Page 86 |
Page 87 |
Page 88 |
Page 89 |
Page 90 |
Page 91 |
Page 92 |
Page 93 |
Page 94 |
Page 95 |
Page 96 |
Page 97 |
Page 98 |
Page 99 |
Page 100 |
Page 101 |
Page 102 |
Page 103 |
Page 104 |
Page 105 |
Page 106 |
Page 107 |
Page 108 |
Page 109 |
Page 110 |
Page 111 |
Page 112 |
Page 113 |
Page 114 |
Page 115 |
Page 116 |
Page 117 |
Page 118 |
Page 119 |
Page 120 |
Page 121 |
Page 122 |
Page 123 |
Page 124 |
Page 125 |
Page 126 |
Page 127 |
Page 128 |
Page 129 |
Page 130 |
Page 131 |
Page 132 |
Page 133 |
Page 134 |
Page 135 |
Page 136 |
Page 137 |
Page 138 |
Page 139 |
Page 140